
Evaluate the immunogenicity of LY2963016 insulin glargine (LY IGlar) versus originator Lantus® insulin glargine (IGlar) in Chinese patients with Type 1 or Type 2 diabetes mellitus (T1DM or T2DM). ABES and ABET are prospective, randomized, active control, open label, Phase III studies, enrolled Chinese patients with T1DM (N=272) and T2DM (N=536), respectively. Immunogenicity was evaluated by comparing the proportion of patients with detectable anti‐insulin glargine antibodies and median antibody levels (percent binding) between the treatment groups. The incidence of anti‐insulin antibodies and treatment‐emergent antibody response (TEAR) were compared using the Fisher's exact test or Pearson's Chi‐square test...
Like
Save
Share